secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001193125-25-114908
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q1 net loss $53.2M; cash $461.7M; taletrectinib PDUFA June 23, 2025
--------------------------------------------------------------------------------

- Net loss of $53.2M ($0.16/share) vs $14.8M ($0.07) in Q1 2024; R&D rose to $24.6M, SG&A to $35.4M.
- Cash, equivalents and marketable securities $461.7M as of March 31, 2025.
- FDA Priority Review for taletrectinib NDA on track; PDUFA goal date June 23, 2025.
- Secured up to $250M non-dilutive financing from Sagard Healthcare; $150M royalty and $50M debt upon FDA approval.
- Appointed Stephen Dang, Ph.D., as Senior Vice President, General Counsel in March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/0001193125-25-114908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-114908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer